BackAcura Pharmaceuticals Overview

Acura Pharmaceuticals Operating Income

Track Acura Pharmaceuticals's operating income ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly Operating Income

N/A

As of Sep 30, 2023

Annual Operating Income (TTM)

N/A

Trailing 12 months ending Sep 30, 2023

Average Operating Income (Comparison Companies)

Operating Income History

Operating Income Comparison

Annual Operating Income Growth Rate (%)

Annual Operating Income Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin

Acura Pharmaceuticals (ACUR) FAQ

As of the most recent data (September 2023), ACUR shows a operating income of $0. That compares with $-1.1M in the prior-year period — up 100.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ACUR's operating income is now $0 (was $-1.1M) — a 100.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Acura Pharmaceuticals is outperforming or lagging.

Tracking ACUR's operating income over time shows whether Acura Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $0 That compares with $-1.1M in the prior-year period — up 100.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has Acura Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $0) with ownership activity and broader fundamentals.